Phase III international, randomized study of Trabectedin plus Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin plus PLD in patients with ovarian cancer progressing within 6-12 months of last platinum

Trial Profile

Phase III international, randomized study of Trabectedin plus Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin plus PLD in patients with ovarian cancer progressing within 6-12 months of last platinum

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 24 Jul 2018

At a glance

  • Drugs Trabectedin (Primary) ; Carboplatin; Doxorubicin liposomal
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms INOVATYON
  • Most Recent Events

    • 16 Jul 2018 Planned End Date changed from 1 Dec 2019 to 1 Jul 2020.
    • 16 Jul 2018 Planned primary completion date changed from 1 Dec 2019 to 1 Jul 2020.
    • 16 Jul 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top